51. Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action
- Author
-
Darren C. Tomlinson, Robin L. Owen, Colin W. G. Fishwick, James I. Robinson, J.E. Nettleship, Maren Thomsen, Raymond J. Owens, Adrian Goldman, Michael J. McPherson, Mark P. Waterhouse, Christian Tiede, Euan W. Baxter, Richard Foster, Stephanie J. Win, Sarah A. Harris, and Ann W. Morgan
- Subjects
0301 basic medicine ,Multidisciplinary ,Affimer ,Chemistry ,Allosteric regulation ,Receptors, IgG ,Antigen-Antibody Complex ,Molecular Dynamics Simulation ,DNA-binding protein ,Immune complex ,3. Good health ,Cell biology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Immune system ,Allosteric Regulation ,PNAS Plus ,IgG binding ,Immunoglobulin G ,Humans ,Tumor necrosis factor alpha ,Receptor ,030217 neurology & neurosurgery - Abstract
Significance Autoimmune disease pathogenesis is driven by inflammation, induced partly by IgG autoantibody-containing immune complexes binding to Fc gamma receptors (FcγRs). These receptors are valid therapeutic targets in the treatment of autoimmunity. FcγRIIIa is one of a family of highly homologous receptors for IgG antibodies; previous attempts at therapeutic blockade have resulted in off-target effects involving cells that express the almost identical protein FcγRIIIb. Here we report the identification of functionally specific protein-based inhibitors (Affimer proteins) of FcγRIIIa and the structural/functional basis of their selectivity. As molecular research tools FcγRIIIa-specific Affimer proteins provide the ability to block IgG interaction with a single receptor. Our findings suggest that highly selective protein-based blocking agents that may have therapeutic applications can be readily produced.
- Published
- 2018